Cargando…

The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): PSIDER (ZOn-MW) PREDICT2 (Hartstichting) BACKGROUND: The PLN p.Arg14del risk model is a mutation-specific risk model developed to predict individual malignant ventricular arrhythmia (VA) risk to inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Der Heide, M Y C, Verstraelen, T E, Van Lint, F H M, Bosman, L P, De Brouwer, R, Proost, V M, Germans, T, Dickhoff, C, Schoonderwoerd, B A, Houweling, A C, Gimeno-Blanes, J R, De Boer, R A, Cox, M G P J, Van Tintelen, P, Wilde, A A M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398618/
http://dx.doi.org/10.1093/europace/euad122.344
_version_ 1785084091422474240
author Van Der Heide, M Y C
Verstraelen, T E
Van Lint, F H M
Bosman, L P
De Brouwer, R
Proost, V M
Germans, T
Dickhoff, C
Schoonderwoerd, B A
Houweling, A C
Gimeno-Blanes, J R
De Boer, R A
Cox, M G P J
Van Tintelen, P
Wilde, A A M
author_facet Van Der Heide, M Y C
Verstraelen, T E
Van Lint, F H M
Bosman, L P
De Brouwer, R
Proost, V M
Germans, T
Dickhoff, C
Schoonderwoerd, B A
Houweling, A C
Gimeno-Blanes, J R
De Boer, R A
Cox, M G P J
Van Tintelen, P
Wilde, A A M
author_sort Van Der Heide, M Y C
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): PSIDER (ZOn-MW) PREDICT2 (Hartstichting) BACKGROUND: The PLN p.Arg14del risk model is a mutation-specific risk model developed to predict individual malignant ventricular arrhythmia (VA) risk to inform decision-making for primary prevention implantable cardioverter defibrillator (ICD) implantation. While the risk model has proven to be valid, two main points of criticisms remain to be discussed: first, the risk model is only validated at baseline and second, appropriate ICD therapy and sustained ventricular tachycardia (VT) <250 bpm is an imperfect surrogate outcome for SCD. PURPOSE: To evaluate the diagnostic performance of the PLN p.Arg14del risk model longitudinal at 3 year follow-up and to reevaluate the predictors regarding SCD. METHODS: Clinical data of 278 PLN p.Arg14del mutation carriers with no history of malignant VA at both baseline and 3 year follow-up were collected. During a median follow-up of 4 years (Interquartile range (IQR) 1.8-6.5), 31 (11%) carriers experienced malignant VA, defined as sustained VA, appropriate ICD intervention, or (aborted) SCD. The reevaluation of the predictors with the 3 year follow up data revealed hazard ratio’s (HR) that were similar to the baseline PLN p.Arg14del risk model for left ventricular ejection fraction (HR 1.10 [95% CI, 1.06-1.12], p<0.001), low-voltage ECG (HR 12.24 [95% CI, 5.21-28.8], p<0.001) and the PVC count per 24h (HR 1.51 [1.15-1.98], p=0.003). The 5-year malignant VA risk was divided into tertiles of predicted risk. The tertiles clearly demonstrated good discrimination between risk group as shown in figure 1 and this resulted in an C-statistic of 0.85 (95% CI 0.78-0.92). To reevaluate the predictive performance of the PLN p.Arg14del risk model for a more strict surrogate of SCD we redefined the outcome as VT >250 beats per minute sustained (lasting ≥30 seconds) or terminated by ICD, ventricular fibrillation, aborted SCD and SCD. We included 669 PLN p.Arg14del carriers with no presentation or history of sustained VA or (aborted) SCD. During a median follow-up of 4.75 years (IQR 1.9-7.9), 33 (5%) carriers experienced the outcome. Results of the univariable analysis are shown in table 1. The PLN p.Arg14del risk model yielded a C-statistic of 0.75 (95% CI 0.70-0.80). Adding risk factors sex, age and sustained VT <250 bpm did not change its performance. CONCLUSION: The PLN p.Arg14del risk model was validated longitudinal at 3 year follow-up and it held its performance with a more strict definition of SCD. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10398618
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-103986182023-08-04 The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD) Van Der Heide, M Y C Verstraelen, T E Van Lint, F H M Bosman, L P De Brouwer, R Proost, V M Germans, T Dickhoff, C Schoonderwoerd, B A Houweling, A C Gimeno-Blanes, J R De Boer, R A Cox, M G P J Van Tintelen, P Wilde, A A M Europace 13.4.4 - Device Treatment FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): PSIDER (ZOn-MW) PREDICT2 (Hartstichting) BACKGROUND: The PLN p.Arg14del risk model is a mutation-specific risk model developed to predict individual malignant ventricular arrhythmia (VA) risk to inform decision-making for primary prevention implantable cardioverter defibrillator (ICD) implantation. While the risk model has proven to be valid, two main points of criticisms remain to be discussed: first, the risk model is only validated at baseline and second, appropriate ICD therapy and sustained ventricular tachycardia (VT) <250 bpm is an imperfect surrogate outcome for SCD. PURPOSE: To evaluate the diagnostic performance of the PLN p.Arg14del risk model longitudinal at 3 year follow-up and to reevaluate the predictors regarding SCD. METHODS: Clinical data of 278 PLN p.Arg14del mutation carriers with no history of malignant VA at both baseline and 3 year follow-up were collected. During a median follow-up of 4 years (Interquartile range (IQR) 1.8-6.5), 31 (11%) carriers experienced malignant VA, defined as sustained VA, appropriate ICD intervention, or (aborted) SCD. The reevaluation of the predictors with the 3 year follow up data revealed hazard ratio’s (HR) that were similar to the baseline PLN p.Arg14del risk model for left ventricular ejection fraction (HR 1.10 [95% CI, 1.06-1.12], p<0.001), low-voltage ECG (HR 12.24 [95% CI, 5.21-28.8], p<0.001) and the PVC count per 24h (HR 1.51 [1.15-1.98], p=0.003). The 5-year malignant VA risk was divided into tertiles of predicted risk. The tertiles clearly demonstrated good discrimination between risk group as shown in figure 1 and this resulted in an C-statistic of 0.85 (95% CI 0.78-0.92). To reevaluate the predictive performance of the PLN p.Arg14del risk model for a more strict surrogate of SCD we redefined the outcome as VT >250 beats per minute sustained (lasting ≥30 seconds) or terminated by ICD, ventricular fibrillation, aborted SCD and SCD. We included 669 PLN p.Arg14del carriers with no presentation or history of sustained VA or (aborted) SCD. During a median follow-up of 4.75 years (IQR 1.9-7.9), 33 (5%) carriers experienced the outcome. Results of the univariable analysis are shown in table 1. The PLN p.Arg14del risk model yielded a C-statistic of 0.75 (95% CI 0.70-0.80). Adding risk factors sex, age and sustained VT <250 bpm did not change its performance. CONCLUSION: The PLN p.Arg14del risk model was validated longitudinal at 3 year follow-up and it held its performance with a more strict definition of SCD. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10398618/ http://dx.doi.org/10.1093/europace/euad122.344 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 13.4.4 - Device Treatment
Van Der Heide, M Y C
Verstraelen, T E
Van Lint, F H M
Bosman, L P
De Brouwer, R
Proost, V M
Germans, T
Dickhoff, C
Schoonderwoerd, B A
Houweling, A C
Gimeno-Blanes, J R
De Boer, R A
Cox, M G P J
Van Tintelen, P
Wilde, A A M
The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
title The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
title_full The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
title_fullStr The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
title_full_unstemmed The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
title_short The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
title_sort phospholamban (pln) p.arg14del risk model; longitudinal validation and reevaluation of predictors regarding sudden cardiac death (scd)
topic 13.4.4 - Device Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398618/
http://dx.doi.org/10.1093/europace/euad122.344
work_keys_str_mv AT vanderheidemyc thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT verstraelente thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT vanlintfhm thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT bosmanlp thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT debrouwerr thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT proostvm thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT germanst thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT dickhoffc thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT schoonderwoerdba thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT houwelingac thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT gimenoblanesjr thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT deboerra thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT coxmgpj thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT vantintelenp thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT wildeaam thephospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT vanderheidemyc phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT verstraelente phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT vanlintfhm phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT bosmanlp phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT debrouwerr phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT proostvm phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT germanst phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT dickhoffc phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT schoonderwoerdba phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT houwelingac phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT gimenoblanesjr phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT deboerra phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT coxmgpj phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT vantintelenp phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd
AT wildeaam phospholambanplnparg14delriskmodellongitudinalvalidationandreevaluationofpredictorsregardingsuddencardiacdeathscd